Today´s health care industry depends greately on complex reseach and innovation on pharmaceutical, genetics, biotechnology and medical devices sectors. A deeper knowledge in pathophysiology and the epidemiologic transition have driven this changes, creating as well greater market opporrtunities.
In Mexico this service represents 5.5% of GDP and generates about 4% of employment in Mexico (INEGI).
Mexico has the second largest pharmaceutical market in Latin America and it is also one of the world´s main manufacturing centers with presence of 20 multinational pharmaceutical companies. In 2013 the sector was valued at 13.98 billion USD. Meanwhile for that same year the exports of medical devices reached 6.89 billion USD. Mexico is the main supplier to the U.S. market.
It is expected that by 2025 the customer engagement within the health sector will be through electronic media in relation to laboratory tests, medications, and medical consultations.
It is important to emphasize that this industry is bound to strict rules and regulations in Mexico and many other countries, that must be carefully analized before entering to the market. ARNI Consulting Group can guide you in this process and help you improve your business strategy.